Abstract | Mathematically modelling changes in HCV RNA levels measured in patients who receive antiviral therapy has yielded many insights into the pathogenesis and effects of treatment on the virus. By determining how rapidly HCV is cleared when viral replication is interrupted by a therapy, one can deduce how rapidly the virus is produced in patients before treatment. This knowledge, coupled with estimates of the HCV mutation rate, enables one to estimate the frequency with which drug resistant variants arise. Modelling HCV also permits the deduction of the effectiveness of an antiviral agent at blocking HCV replication from the magnitude of the initial viral decline. One can also estimate the lifespan of an HCV-infected cell from the slope of the subsequent viral decline and determine the duration of therapy needed to cure infection. The original understanding of HCV RNA decline under interferon-based therapies obtained by modelling needed to be revised in order to interpret the HCV RNA decline kinetics seen when using direct-acting antiviral agents (DAAs). There also exist unresolved issues involving understanding therapies with combinations of DAAs, such as the presence of detectable HCV RNA at the end of therapy in patients who nonetheless have a sustained virologic response.
Introduction
HCV research and treatment has entered a new era with the advent of direct-acting antiviral agents (DAAs) that are safe, orally deliverable, and with a short treatment duration can cure HCV infection in nearly every patient. 1 Some of the rapid advances in bringing new therapeutics to the clinic have their basis in mathematical modelling, which provided tools to rapidly assess the in vivo effects of new antivirals. Terms that were originally used as mathematical characterizations of viral kinetics, such as the first and second phase of viral decline, have become phrases familiar to almost all researchers and clinicians in the field. In this Review, we provide insights into these developments and show how the early concepts in HCV viral dynamics developed from the study of patient responses to interferon (IFN)-based therapies have had to change in order to understand the effects of DAA-based therapies. Furthermore, as we look to the future, both modellers and clinicians want to know how short the period of treatment can be made when DAA combinations are used. Will curing some individuals with 4 weeks or 2 weeks of treatment be possible? What are the barriers to rapid cure? How can we evaluate if a patient is on track to be cured rapidly or if longer treatment durations are needed? In this Review we will not directly answer these questions, but we will discuss the mathematical models and c oncepts required to answer such questions.
Modelling IFN-based therapy
Dynamic equilibrium in absence of treatment One of the most important insights into viral kinetic modelling has its origins in work that modelled the effects of antiretroviral treatment for HIV. [2] [3] [4] [5] This insight is based on the simple heuristic argument that a change in viral load reflects an imbalance between the antagonistic processes of viral production and clearance and can be mathematically written as Equation 1 dV/dt = pI -cV (1) where V is the viral load, dV/dt is rate of viral load change, p is the rate of virus production per infected cell, I, and c is the per virion rate of viral clearance (that is, the virion half-life: ln(2)/c). During chronic infection, the viral load is stable and remains roughly equal to a set-point level denoted V 0 . At the set-point, the rates of viral production and viral elimination balance so that pI 0 = cV 0 , where the set-point number of infected cells is I 0 .
The first phase of viral decline
The initiation of anti-HCV treatment disrupts the equilibrium between virus and host. Most antivirals (such as IFN or DAAs) block viral production and, therefore, reduce p, by a factor of (1 -ε) , where ε is the effectiveness of therapy that varies between 0 and 1, and 1 represents a 100% effective therapy. Neumann et al. 6 showed that Equation 1, with p replaced by (1 -ε)p, predicted that the viral load will decrease according to Equation 2 V(t) = V 0 (1 -ε + εe -ct )
for a short period of time after the initiation of therapy, during which the viral production rate pI remains approximately constant and equal to pI 0 . The exponential term in Equation 2 approaches 0 as time proceeds, therefore, the viral load will decline to the value V 0 (1 -ε), reflecting that treatment leads to lower levels of viral production. This assertion implies that if a drug is 99% effective then the viral load should decrease to 0.01 V 0 . Consequently, one can calculate the effectiveness of a drug that blocks viral production by the log 10 viral decline it causes, that is, if a drug results in a 2 log 10 decline then it is 99% effective. This model has been used to fit viral load data obtained from patients infected with HCV genotype 1 who were treated with different doses of IFN-α and sampled every few hours during the first 2 days and daily for 2 weeks after drug therapy was started. 6 After a delay of ~8 h, which reflected the time for IFN to bind to cellular receptors and lead to upregulation of IFN-stimulated genes, 7 HCV RNA levels declined rapidly for the first day (Figure 1a) , with a clearance rate c ~6/day corresponding to a half-life of HCV in the circulation of ~2.7 h. 6 Furthermore, the extent of decline was dependent on IFN dose corresponding to a dose-dependent Key points ■ After patients receive therapy for HCV infection, HCV RNA declines in a biphasic manner, the first phase reflects viral clearance, the second phase the loss of infected cells ■ The use of mathematical modelling reveals that high viral production enables the daily production of all single or double mutant variants resulting in drug resistance for therapies with low genetic barriers ■ Modelling HCV RNA kinetics has enabled researchers to estimate the effectiveness of therapy and optimal treatment duration to achieve a sustained virologic response (SVR) ■ Multiscale models that include intracellular viral replication and extracellular spread indicate that NS5A and protease inhibitors can inhibit both viral replication and viral assembly or release ■ Interferon-free combination therapies are available, have little resistance and can generate a SVR after treatment times as short as 6 weeks ■ HCV RNA has been detected after treatment with some direct-acting antiviral combinations in patients who develop a SVR, but viral kinetic theory cannot currently explain this phenomenon effectiveness in blocking viral production. 6 Importantly, if HCV is rapidly eliminated from serum it implies that large quantities of virus need to be produced every day (about 10 11 to 10 12 virions) to maintain set-point viral levels of 10 6 to 10 7 HCV RNA copies/ml of serum in the absence of treatment.
The second phase of viral decline After day 2, the viral load does not plateau, as predicted by Equation 2, but rather continues to decline, albeit with a slower rate (Figure 1b ). This failure of Equation 2 to continue to correctly predict the kinetics of viral decline reflects the fact that the rate of viral production begins to drop as infected cells die and are not efficiently replaced owing to the viral load decline during the first phase. 8 As the number of newly infected cells declines, overall viral production is further reduced. Consequently, the effect of treatment, even if modest, triggers a cycle of events that leads to a continuous decline of virus and infected cells, that is, the second phase, which continues as long as treatment is maintained. Mathematical analysis reveals that the rate of this decline is approximately equal to δε, where δ is the loss rate of infected cells. 6 Therefore, for potent drugs, where ε ~1, the second phase slope is approximately δ.
Extended models
Although the biphasic model provides the basic foundation for understanding the determinants of early viral decline, more complex models have been introduced to understand the role of liver regeneration, drug pharmacokinetics and the effects of ribavirin. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Because the putative effects of ribavirin have been extensively reviewed elsewhere they will not be discussed here. 10, 11, [25] [26] [27] [28] [29] Liver regeneration An important prediction of models that account for hepato cyte proliferation is the existence of a threshold, known as the 'critical drug effectiveness' (ε c ). 16 If ε < ε c , the virus is not eradicated sufficiently rapidly and the progressive replenishment of target cells over time enables the remaining virus to infect new cells and establish a new, lower, set-point despite ongoing therapy. 16 Interestingly, mathematical analysis of these models reveals that the value of ε c depends on, and increases with, parameters that determine the baseline HCV RNA level and the proportion of infected cells. 18 These models might, therefore, explain why high baseline viral loads and the presence of advanced fibrosis are negatively correlated with sustained virologic response (SVR). 30 Drug pharmacokinetics Viral rebound can be due to a loss of drug effectiveness over time owing to lower drug concentrations towards the end of the dosing period, and is sometimes seen with weekly administration of PEG-IFN. 9, 13, 19 The relationship between drug concentration and anti viral effectiveness in blocking viral production can be described by an E max model (Equation 3) where C(t) is the drug concentration at time t; EC 50 is the drug concentration needed to achieve an effectiveness of 50% of the maximum effect, E max ; and n is the Hill coefficient, a constant that determines the steepness of the drug concentration-effect curve. 22, 31 Because drug concentrations are sometimes unavailable, empirical models have also been proposed to describe the patterns of change in drug effectiveness over time, 32, 33 such as an exponential model for drugs whose concentrations decay or build up over time (Equation 4)
where the treatment effectiveness starts from an initial level, ε 1 , changes to a final level, ε 2 , with k ε representing the rate of change of effectiveness. Therefore, if ε 2 < ε 1 the model can mimic the effect of a decrease in drug effectiveness over time, as observed for example near the end of the dosing interval with weekly PEG-IFN. 32, 34 Conversely, if ε 2 > ε 1 the model can mimic the effect of an increase in drug effectiveness over time, as is the case with some DAAs for which the short half-life or the time to achieve high levels of active metabolites might induce a delay until the drug is fully effective. 24, 31, [35] [36] [37] [38] [39] Although the models described in this section have been useful to analyse early changes in viral load with IFN and some DAAs, they are limited by the fact that the models assume that treatment simply blocks production of a drugsensitive virus. To understand the patterns observed during DAA treatment, such as the origin of the accelerated viral decay, one needs models that account for the different stages of viral replication targeted by DAAs.
Viral kinetics with DAAs
Blocking virion assembly and secretion Because the NS5A protein, which has a central function in HCV replication, has no enzymatic functions, the effect of blocking this protein has been poorly understood. Using an innovative screening approach to identify compounds that were functionally distinct from those acting on the NS3 protease and the NS5B RNA-dependent RNA-polymerase, investigators identified that the NS5A inhibitor daclatasvir could be an important compound for anti-HCV treatment. 40 The viral kinetics observed when a patient receives daclatasvir reveal a first phase of viral decline that is much faster than that seen with other treatments, 40 such as with IFN, 6 PEG-IFN plus ribavirin, 41 the protease inhibitor telaprevir, 35, 41 and the polymerase inhibitors mericitabine 42 and sofosbuvir 37 ( Figure 2a) . 40, 43 In fact, HCV RNA levels can decline by as much as 3 logs in 12 h after a single dose of daclatasvir, 40 from which it was deduced that HCV RNA cleared from the circulation with a half-life of 45 min 43 and not the previously estimated 2-3 h half-life based on the response to IFN-based therapy. 6, 44 In order to explain this discrepancy in viral clearance rates it was hypothesized that if NS5A inhibitors potently block both viral secretion and replication, then the viral load will decrease more rapidly than with therapies that block viral replication alone. 43 If a therapy mainly inhibits viral replication, then viral RNA present within infected cells when therapy is started can continue to be packaged into virions and exported after drug therapy is initiated. In this situation, viral production continues and results in an underestimate of the viral clearance rate. 43 To precisely characterize the effect of daclatasvir, a multi scale model was developed ( Figure 3) . 43 An important feature of this model was that the number of viral RNA molecules, R(a,t), within an infected cell was modelled as a function of the length of time, a, the cell had been infected and the time the patient had been exposed to therapy, t. Within an infected cell, viral RNAs accumulate as they are synthesized and decrease in number as they are degraded or assembled into virions, which are then secreted. This multiscale model, therefore, includes the 42 IFN 10 or 15 MIU once daily (beige), 6 sofosbuvir 400 mg once daily (red), 37 telaprevir 750 mg every 8 h (blue) 35 and a single dose of daclatasvir (10 or 100 mg, purple). 43 b | Combination therapy with IFN 10 or 15 MIU once daily (beige), 6 sofosbuvir 400 mg once daily + ribavirin (red), 57 telaprevir 750 mg every 8 h plus PEG-IFN 35 (blue) and sofosbuvir 400 mg once daily plus ledipasvir 90 mg once daily (purple). 61 HCV RNA measurements: circles. Nonparametric kinetic fitting: lines.
drug effectiveness in blocking viral RNA production, ε α , the drug effectiveness in blocking viral assembly or secretion, ε s , and its effectiveness in modulating the rate of viral RNA degradation, κ (that is, κ >1 if a drug enhances the rate of viral RNA degradation). 43 Converting the multiscale model into a set of equations is complicated and beyond the scope of this Review; however, for interested readers the mathematical formulation and analysis of the model can be found in a number of publications. 8, 43, 45 Using the multiscale model to fit the viral decline during the first 2 days of IFN and daclatasvir treatment led to the conclusion that daclatasvir has a dual mode of action, efficiently blocking viral RNA production (ε α = 0.99), and inhibiting virus assembly and secretion (ε s = 0.998). 43 Daily IFN treatment was predicted to have a small effect on assembly and secretion (ε s = 0.39) and its main effect at doses of 10 and 15 million IU was on viral replication (ε α = 0.96). Viral declines seen with the protease inhibitors telaprevir and danoprevir were also faster than those observed during IFN-based therapy (Figure 2a) . Although telaprevir and danoprevir were found to have an inhibitory effect on virion assembly and secretion (ε s = 0.95 and 0.56, respectively) 43,45 the effect was not as profound as that of daclatasvir. 43, 45 This finding might explain why the virion clearance rate estimated for patients treated with telaprevir (c = 12/day) 34, 44 was higher than that of patients treated with IFN (c = 6/day) 35, 41 but not as high as for those treated with daclatasvir (c = 22/day). 43 Interestingly, the predictions that NS5A inhibitors and protease inhibitors affect both viral replication and virion assembly and secretion are now supported by in vitro experiments. 43, 46, 47 Furthermore, IFN has been shown to rapidly affect in fectious particle genesis. 48 The intracellular model used in the multiscale model is simplistic in that only positive-strand HCV RNA is described (Figure 3) . More complex models of intracellular replication than the multiscale model, which include features such as the replication complex, HCV RNA proteins and the membraneous web, have also been developed. 49, 50 However, using such models to fit clinical data within the context of a multiscale model remains challenging as too many unknown parameters exist to reliably estimate from the available data.
Curing infected cells
Although standard dynamic models attributed the second phase of viral decline to the death of infected cells, 6, 44, 51 the fast second phase decline seen with many DAAs, and particularly protease inhibitors, 35, 41, 45, 52 has questioned this assumption. A more plausible assumption, therefore, is that intracellular penetration of highly effective drugs leads to the cure of infected cells, that is, the treatment results in the loss of intracellular viral RNA. This effect was shown for self-replicating subgenomic HCV RNA in Huh-7 clones after prolonged treatment with IFN-α, and for five HCV genotype 1a H77 replicon cell lines treated with a combination of IFN-α, the NS3 protease inhibitor BILN-2061 (ciluprevir), and the NS5B polymerase inhibitor GS-9190 (tegobuvir). 53, 54 In addition, some DAAs, in particular protease inhibitors, might also restore innate immune responses within infected cells and these responses can contribute to a rapid loss of intracellular viral RNA. 55 However, whether the in vivo concentrations of these drugs are high enough to generate this effect has been questioned by some investigators. 56 Interestingly, nucleoside and nucleotide polymerase inhibitors do not have as fast second phase declines as the HCV protease inhibitors. 37, 42 For example, the viral declines induced by the HCV polymerase inhibitor sofosbuvir (either alone or in combination with riba virin or another nucleotide analogue) have been modelled, and the second phase decline slope δ was estimated to be 0.2-0.3/day in treatment-naive patients. 37, 57 This decline is faster than the average 0.14/day decline seen using IFN-based therapies, 6 ,51 but slower than the 0.5-0.6/day associated with telaprevir monotherapy o r in combination with PEG-IFN, again in treatment-naive patients (Figure 2 ). 35 The possibility that the rapid second phase viral declines seen in response to protease inhibitors might be the result Nature Reviews | Gastroenterology & Hepatology of infected cells being cured led to a proposed model that included the effect of DAAs on intracellular viral replication. 58 In this 'intracellular and cellular infection' model, both positive-strand HCV RNA and replication complexes within infected cells were incorporated. Using this model, the investigators demonstrated that drugs resulting in a continuous loss of replication complexes at rate γ, can generate an accelerated second phase of viral decline with slope δ + γ. 58 The model, therefore, predicted that the second phase viral decline was the result of a combined effect of infected cell death and reduced levels of viral re plication in the remaining infected cells.
The majority of viral kinetic analyses of DAA-based treatments have been performed for treatment-naive patients who do not have cirrhosis. 35, 37, [41] [42] [43] Results obtained in studies involving small patient populations found a much slower second phase of viral decline in patients with cirrhosis or in treatment-experienced patients, than in treatment-naive patients without cirrhosis. 59, 60 More data are now needed to precisely evaluate the second phase of viral kinetics with DAAs in 'real life' situations in which the proportion of patients with unfavourable characteristics (that is, cirrhosis or those who are treatment experienced) is often larger than in clinical trials.
Implications for treatment duration
Regardless of its origin, a rapid second phase of viral decline should allow for shorter treatment duration. To predict the time needed to eradicate HCV, a theoretical threshold, known as a 'cure boundary' has been introduced into mathematical models. 11, 51 The cure boundary can be defined as having less than one viral particle in the extracellular body fluid (that is, 15 l), and corresponds to a concentration of 10 -4.22 IU/ml. 11 Using this cure boundary, eradication requires the viral load to decline >10 log 10 from a typical baseline of 10 6 IU/ml. 11 With current assay limits of detection of about 10 IU/ml 61, 62 approximately another 5 logs of viral decline are still needed before the viral load hits the cure boundary (Figure 4a ). Other investigators 51 have defined the cure boundary as having fewer than one virus infected cell, which is a conservative assumption and delays the predicted time to eradication by 2-3 weeks using standard parameter values. 35 Treatment duration can easily be predicted from the first and second phases of viral decline using the cure boundary concept. By analysing the rapid viral decline in patients treated with danoprevir, a protease inhibitor, and mericitabine, a polymerase inhibitor, this approach led to the prediction that between 8 and 12 weeks of treatment should be sufficient to cure patients treated with DAAs. 63 Furthermore, in a study simulating a clinical trial in which the first and second phase declines of patients were chosen at random from the parameter distributions estimated in patients treated with telaprevir, 95% of patients could obtain SVR (defined as having less than one virion remaining) in 7 weeks. 35 This result assumes that the patients fully complied with their therapy and that the predicted second phase decline continued unchanged when it is below the limit of detection (Figure 4b) . 35 This situation could arise only if the treatment has a sufficiently high genetic barrier to resistance and no viral reservoirs are present. In fact, SVR rates obtained after 12 or 24 weeks of treatment with danoprevir and meri citabine were low, and virologic breakthrough or relapse were associated with danoprevir-resistant virus in most cases. 64 Similarly, the prediction of 7 weeks of therapy to obtain 95% SVR would not apply to telaprevir monotherapy, but rather to a combination DAA therapy that can prevent resistance development, and which has the kinetic characteristics of short-term telaprevir therapy.
Interestingly, the results of several clinical trials have now validated the prediction that SVR can be achieved in a large fraction of non-cirrotic treatment-naive patients who received 8 weeks or less of treatment with some DAA combinations. 61, 65, 66 For example, in the ION-3 trial, 65 among previously untreated patients infected with HCV The cure boundary can be based on eliminating the last virus particle (blue circle), eliminating the last infected cell (not shown) or be a threshold beyond which the immune system can contain the infection (red circle). In addition, when the viral load falls below the LOQ, the rate of viral decay can no longer be observed and might change in response to missed drug doses, emergence of drug resistance, viral reservoirs or other factors. Consequently, the time needed to hit the cure boundary might be extended (blue dashed line). b | Estimated cumulative probability distribution function for the treatment duration needed to eliminate the last remaining virus particle. The beige line corresponds to perfect treatment adherence, whereas the red line represents the case of partial adherence to a regime of three doses per day, for which one dose is randomly missed every 2 days. Abbreviation: LOQ, limit of quantification. Permission obtained from Wiley © Guedj, J. et al. Hepatology 53, 1801-1808 (2011).
35
REVIEWS genotype 1 but without cirrhosis, SVR12 was 94% after 8 weeks of treatment with sofosobuvir and ledipasvir. In the C-WORTHY trial, 66 among patients with previously untreated infection with HCV genotype 1a who received grazoprevir and elbasvir for 8 weeks, SVR12 was 80%. Finally, in the SYNERGY trial, 61 among treatment-naive patients infected with HCV genotype 1 who received sofosobuvir, ledipasvir and either GS-9669 (a nonnucleoside NS5B inhibitor) or GS-9451 (an NS3/4A protease i nhibitor) SVR12 was 95% after 6 weeks of treatment.
The prediction of treatment outcome can be further improved by including pharmacokinetic data to account for the effect of drug exposure on the response to treatment and predict the effect of different dosing regimens. 51, [67] [68] [69] For example, the viral kinetics observed in patients treated for 4 weeks with various doses of a lisporivir (a cyclophilin inhibitor) or alisporivir-PEG-IFN have been modelled. 23, 69 The investigators used what has been called a PK-VK model, that is, a standard viral kinetic (VK) model, 6 in which the drug effectiveness depends on drug concentration that in turn is determined by a pharmacokinetic (PK) model, to accurately predict the SVR rate of a subsequent clinical study with a 24 week treatment duration and different doses of alisporivir. 23 These results highlight how modelling of short-term data can be used to anticipate the outcome in a complex clinical trial.
Modelling drug resistance
The emergence of drug-resistant HCV variants can mean that the second phase of viral decline might not be sustained and the treatment duration predicted from the second phase might be inaccurate. 35, 70, 71 In fact, viral breakthrough owing to drug resistance was shown to occur as early as 2 days after initiation of telaprevir monotherapy, with 5-20% of clones sequenced found to carry known resistance mutations. 70 Furthermore, the virus rapidly rebounded and by the end of therapy at day 14 almost all virus was drug resistant. 70 Given that HCV has a high daily production rate 6 and a high error rate during replication, 72, 73 all viable single and double mutant resistant viruses might exist before treatment and compete with wild-type virus during therapy. 74 This calculation led to the prediction that only treatments with a high genetic barrier to resistance can lead to SVR. 74 Viral competition has a crucial role in deter mining long-term viral decline. Mathematical models have, therefore, been expanded to include both drug-sensitive and drug-resistan t virus, 74 or wild-type plus multiple viral strains as well as cells infected with these various viral strains. 68, 71, 75, 76 In the framework of these models, viral eradication can be achieved only if the different variants are sufficiently sensitive to treatment or have a low fitness, that is, a low capability to grow.
However, the mechanism underlying the rapid rebound of resistant virus is not fully understood. A resistant virus needs 'replication space' to grow in number. In some models, the rapid expansion of a mutant, drug-resistant, virus is supported by the infection of newly produced hepatocytes. 71, 74 However, this assumption has not been validated because little quantitative data exists regarding hepatocyte kinetics in HCV-infected livers. The replication space might also be supplied by other mechanisms, such as 'superinfection' , that is, reinfection of cells previously infected with wild-type virus or the loss of an IFN-induced antiviral state due to decreased viral levels. Although experiments largely support the notion of superinfection exclusion (that is, a prevention of secondary infection by a preexisting viral infection), some superinfection has been observed in vitro. [77] [78] [79] Furthermore, for recombination of HCV genomes to occur, multiple viruses must infect a single cell. Recombinant forms of HCV have also been identified, 80 which provides support for the occurrence of in vivo superinfection. The loss of IFN-induced antiviral states has been included in a viral kinetic model of influenza infection, 81 but to our knowledge not in models of HCV infection, and leads to increased replication space. Understanding the mechanism of drug-resistant virus expansion and subsequent treatment failure might enable the design of improved combination therapies that target both the virus and its host.
Predicting future treatment effects
Modelling potent drug combination in vivo In the future, most treatments for HCV will involve IFN-free combinations of DAAs. Standard or multiscale models can be expanded to account for drug combinations using pharmacological concepts of drug additivity and synergy, 82, 83 or by simply analysing the HCV RNA decline kinetics and estimating the overall effectiveness of the combination therapy. From a mathematical modelling perspective, two interesting clinical trials of DAAs have been the SPARE 57 and SYNERGY trials. 61 In SPARE, 60 treatment-naive patients infected with HCV genotype 1 received 400 mg daily of sofosbuvir plus ribavirin for 24 weeks. In the SYNERGY trial, 61 60 patients who were also treatment naive and infected with HCV genotype 1 were randomly assigned (1:1:1) to receive sofosbuvir and ledipasvir for 12 weeks (arm A), sofosbuvir and ledipasvir plus the non-nucleoside polymerase inhibitor GS-9669 for 6 weeks (arm B) or sofosbuvir and ledipasvir plus polymerase inhibitor GS-9451 for 6 weeks (arm C). The viral load decline in all three arms of the SYNERGY trial was initially more rapid than in patients treated with sofosbuvir plus ribavirin, which can be attributed to a high effectiveness of the NS5A inhibitor ledipasvir in blocking viral assembly and secretion. 46 However, by day 3, patients treated with sofosbuvir plus ribavirin achieved largely comparable levels of virus as the patients in all arms of SYNERGY, which suggest two possibilities: firstly, in spite of an additive effect in vitro, 84 sofosbuvir and ledipasvir did not have a larger effect in blocking viral RNA production in vivo than sofosbuvir plus ribavirin; and secondly, that the possibility of shorter treatment with sofosbuvir and ledipasvir was not due to faster kinetics of viral decline. Furthermore, based on the observed viral decline kinetics in arms B and C of SYNERGY, one would predict an SVR rate of <30% (based on eliminating the last virus particle after 6 weeks of treatment) and not the 95% observed. 61 Is HCV RNA still a reliable biomarker? Another unexpected finding in arms B and C of the SYNERGY trial was that at the end of treatment (at week 6), 12 of 20 patients (60%) in arm B and 10 of 20 (50%) in arm C, had detectable HCV RNA levels, which is over the 3 IU/ml detection limit of the highly sensitive Abbott RealTime™ HCV assay (Abbott Laboratories, IL, USA). 61 Having HCV RNA levels close to the detection limit implies that viral eradication is still far off; in fact, standard mathematical modelling tools predict that ~1 million virions are still produced each day. 6 Consequently, all existing mathematical models of HCV would predict that patients with detectable viraemia will progressively rebound as active intracellular drug decayed after the end of treatment (EOT). However, in SYNERGY only one patient in study arm B had a viral rebound (one patient in arm C was lost to follow-up after reaching SVR4). 61 Consequently, the notion of a cure boundary corresponding to the loss of the last viral particle or last infected cell at the EOT does not seem to be a valid criterion for cure with these DAAs. This situation in the SYNERGY trial is not an isolated incident. For example, in a phase IIa trial (PILOT study) in which 11 patients infected with HCV genotype 1 received a NS3A protease inhibitor co-dosed with low dose ritonavir, a non-nucleoside NS5B polymerase inhibitor and ribavirin for 12 weeks, residual viraemia was detected by the Abbott RealTime™ HCV assay (Abbott Laboratories, IL, USA) at therapy weeks 9, 10 and 12 in three patients who ultimately achieved SVR. 62 These observations, as well as the finding that among five participants in the SYNERGY trial who achieved SVR12, four had quantifiable HCV RNA measured 2 weeks after completing therapy (range 15-57 IU/ml) and another participant had 14 IU/ml of HCV RNA measured 4 weeks after EOT, 85 also raise the possibility that HCV RNA levels post-treatment might not be useful in clinical decision-making. Currently no proven explanation has been presented for the lack of viral rebound in patients with detectable HCV RNA at EOT in the SYNERGY and PILOT studies. However, two obvious possibilities exist: firstly, the immune system controls the virus, which results in a functional cure, as reported in rare instances in patients infected with HIV who ceased therapy; 86, 87 or that the HCV RNA detected by the high sensitivity assay was not infectious. 88 A related concern has been the phenomenon of late viral relapse. In a small phase IIa trial involving 11 patients given two DAAs (ABT-450/r and ABT-072) plus ribavirin for 12 weeks, one patient relapsed at posttreatment week 36 with a virus that was most likely the baseline strain determined by sequence analysis. 89 Other cases of very late relapse have also been published, 90, 91 which might support the idea of breakthrough from immune control or the existence of viral reservoirs, that is, infected cells that are not eradicated by treatment and might activate after the EOT. Consistent with an important role of immune system suppression of HCV, trace amounts of HCV RNA in plasma were sporadically found in patients up to 8 years after s uccessful therapy. 92 More data are needed to assess whether other DAA combinations give rise to the same phenomenon and if clinical treatment algorithms based on the time to achieve undetectable viraemia need to be revised for new treatments. Given the potential importance of the immune system in the control of viral infection, immuno logical data, such as anti-HCV antibody levels, or levels of cytokines, such as C-X-C motif chemokine 10 (also known as interferon γ-induced protein 10) levels, 93 might be correlated to the long-term rate of viral decline and thus help improve SVR prediction.
Conclusions
The use of mathematical models has had an important role in deciphering the kinetics of viral decline during anti-HCV drug therapy, leading the FDA in the USA to recommend its use during drug development. 94 The magnitude of the first phase of viral decline has been used to determine the antiviral effectiveness of drugs that block HCV replication in very short-term clinical trials. New developments, such as the multiscale model, can be used to provide a novel understanding of the origin of the early rapid viral decline with DAAs and gain further information into the modes of action of new antivirals. Mathematical models have also led to the concept of a cure boundary, which can help determine the length of IFN-based therapies. With some new DAA combinations, high SVR rates have been obtained after 6-12 weeks of therapy. However, some patients on this short duration therapy have a slow viral decline and detectable HCV RNA at the end of therapy or very late relapses, which suggests that new models are needed to understand the in vivo interactions between DAAs and their effect on viral eradication.
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